Ketamine vs Traditional Antidepressants: Key Differences

If you're among the roughly 30% of people with depression who haven't found relief from multiple antidepressants, you already know what it's like to wait six to eight weeks for a medication to maybe work, only to start over again with the next one. You've probably heard that ketamine therapy works faster and targets different brain pathways. But after being promised results before, skepticism is reasonable.

The bottom line: Ketamine and traditional antidepressants work through entirely different mechanisms. While SSRIs and SNRIs take four to eight weeks to build effectiveness, ketamine can produce relief within hours to days. For people who haven't responded to conventional medications, ketamine offers a biologically distinct approach, not a slightly different version of the same thing.

How Traditional Antidepressants Work

SSRIs (like sertraline, escitalopram, and fluoxetine) and SNRIs (like venlafaxine and duloxetine) increase the availability of serotonin and norepinephrine in your brain's synapses. They're first-line treatments for good reason: well-studied, widely available, and inexpensive at $4–50/month for generics. Side effects like nausea, sleep changes, and sexual dysfunction are common, and if you've dealt with those while waiting for a medication to work, you know how much they can add to an already frustrating process.

The deeper limitation is time. Each medication needs four to eight weeks before you'll know if it's helping, and if it doesn't, you start the clock over with the next one. If you're reading this article, you've probably already lived through more than one of those cycles.

How Ketamine Works Differently

Ketamine is an FDA-approved anesthetic that, at lower doses, produces rapid antidepressant effects through a completely different biological pathway than SSRIs or SNRIs.

Instead of targeting serotonin, ketamine works on glutamate, your brain's most abundant excitatory neurotransmitter. Where serotonin-based medications adjust one part of your brain's signaling, ketamine works on the system responsible for roughly 40% of all synaptic activity. That difference matters because ketamine isn't doing more of what SSRIs do. It's doing something fundamentally different.

In practice, based on animal research with growing support from human studies, the process unfolds in stages:

Stage 1: Releasing the brake. Ketamine blocks NMDA receptors on inhibitory brain cells and removes a "brake" that depression places on neural communication. The result is a surge of glutamate that rapidly strengthens connections in mood-regulating brain regions.

Stage 2: Growth factor release. Within hours, ketamine activates mTOR, your brain's protein-building system. mTOR activation triggers production of brain-derived neurotrophic factor (BDNF), essentially fertilizer for brain cells that supports neuron survival and growth.

Stage 3: New connections form. Within 24 hours, new synaptic connections start forming in brain regions affected by depression, particularly the prefrontal cortex and hippocampus. Animal research confirms this neuroplasticity process, and human studies show symptom relief can begin within 2 hours of a single dose, with peak effects at 24 hours.

How Do Efficacy and Speed Compare?

This is usually the question that matters most: does it actually work better, or just differently?

Two forms of ketamine are currently used for depression. The FDA approved esketamine (Spravato), a nasal spray, in 2019 for adults with treatment-resistant depression when used together with an oral antidepressant, and expanded approval in January 2025 to allow standalone use. Racemic ketamine (containing both S- and R-ketamine) is also used for depression off-label.

The research is encouraging. A meta-analysis of 69 randomized controlled trials [TKTK: verify exact trial count, sample size, and OR from primary paper] found that for treatment-resistant depression, ketamine and esketamine showed an odds ratio of 2.94 compared to placebo (95% CI: 2.03–4.27), while additional SSRI/SNRI augmentation strategies showed no significant benefit. A Cochrane review reinforced this: among 16 drugs reviewed, only ketamine and esketamine were more effective than placebo at reducing depression symptoms.

If you've been through multiple antidepressants, the landmark STAR*D trial helps explain why each one felt less likely to work. Remission rates dropped sharply with each successive trial: roughly 37% achieved remission with a first medication, 31% with a second, about 14% with a third, and 13% with a fourth. After two adequate trials, the odds of finding relief with another conventional antidepressant are low, which is exactly why targeting glutamate instead of serotonin matters.

For someone who has spent months or years cycling through medications, knowing within 24 hours whether a treatment helps changes the entire experience of seeking care.

What Improvement Actually Feels Like

People who respond to ketamine often describe it as the volume turning down on symptoms. The constant background weight of dread or emptiness doesn't vanish overnight, but it quiets enough to function. You might notice you can get out of bed without the usual 45-minute negotiation. A conversation doesn't feel like performing. The things that used to bring you some pleasure start to register again.

With SSRIs, that same shift, if it comes, unfolds so gradually over weeks that you might not recognize it happening. And if the medication isn't working, you've spent two months waiting to find out. That time matters when depression is affecting your relationships, your work, and your ability to show up for your life.

What Are the Side Effect Differences?

The safety profiles differ in type and timing more than in severity.

Ketamine side effects are acute and short-lived. The most common — dissociation, dizziness, nausea, drowsiness, and headache — typically resolve within hours. Blood pressure can temporarily increase during treatment, which is why cardiovascular monitoring is part of the process. Specific eligibility criteria determine who can safely use ketamine.

Traditional antidepressant side effects follow a different pattern. Nausea often improves over weeks, but sexual dysfunction can persist throughout treatment. A particularly challenging issue is discontinuation syndrome: when stopping SSRIs or SNRIs, withdrawal-like symptoms can make it difficult to stop even when clinically appropriate.

The practical difference is that ketamine's side effects are temporary and predictable, while traditional antidepressant side effects may improve, persist, or create new challenges when you try to stop.

If you're wondering about cognitive effects, clinical studies at therapeutic doses in supervised settings haven't shown significant cognitive impairment. Ketamine's safety in clinical settings remains well-supported.

A few open questions are worth knowing about. Optimal maintenance schedules are still being refined, and how often and how long to continue treatment varies by individual. Long-term data beyond a few years is more limited than the decades of research behind SSRIs. The safety profile at therapeutic doses looks strong so far, but the evidence base is still growing.

Which Option Makes Sense for Your Situation?

Rather than an exhaustive checklist, the decision often comes down to where you are in your treatment journey.

If you're still in your first or second medication trial, traditional antidepressants remain the evidence-based starting point. Give them the full four to eight weeks at therapeutic doses before concluding they haven't worked. They're affordable ($4–50/month), require no clinic visits, and have decades of safety data behind them.

If you've tried two or more antidepressants at adequate doses without remission, the research is clear: more of the same class isn't likely to help. If you haven't yet tried a different class, bupropion or mirtazapine work through different mechanisms than SSRIs/SNRIs and may be worth exploring. But if you've already been through multiple classes, ketamine offers a meaningful SSRI alternative that works through the glutamate system rather than serotonin or norepinephrine. VA ketamine treatment guidance has used at least two unsuccessful antidepressant trials as a threshold for considering ketamine.

If your depression is severe enough that waiting another four to eight weeks feels unsustainable, ketamine's rapid assessment timeline matters. Esketamine also carries specific FDA approval for major depression with suicidal ideation or behavior, so it can be appropriate earlier in treatment rather than only after multiple medication failures.

If cost is a primary concern, the landscape varies significantly. Spravato is substantially more expensive than generic antidepressants at list price but is widely covered by major insurers with prior authorization. At-home ketamine programs like Innerwell's can start as low as $54/session with insurance.

Ketamine isn't right for everyone. If you have uncontrolled hypertension, significant vascular disease, current psychosis, schizoaffective disorder, or active substance use disorders, it may not be safe. A clinical evaluation would determine that before you start.

Ketamine also isn't the only option beyond antidepressants. Electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) are established treatments for treatment-resistant depression. A large NEJM trial found ketamine noninferior to ECT, with fewer cognitive side effects and no persistent memory impairment reported in the trial.

How Innerwell's At-Home Ketamine Therapy Works

If you've reached the point where traditional antidepressants haven't worked and you're weighing ketamine as a next step, the practical question becomes: what does treatment actually look like, and does it matter who provides it?

It does. Early studies and clinical experience suggest ketamine works best when combined with psychotherapy. The neuroplasticity window the medication creates is most valuable when you use it intentionally. The medication opens a door; integration therapy helps you walk through it. Without therapeutic support, effects may not last as long.

Innerwell pairs sublingual ketamine treatment with licensed psychotherapist support. This isn't ketamine dropped off with minimal supervision. It's comprehensive mental health care guided by Master's and Doctoral level clinicians, not unlicensed guides.

The process:

1. Evaluation: A psychiatric provider reviews your history, current medications, and what you've already tried. The assessment is thorough, designed to make sure ketamine is safe and appropriate for your situation.
2. Delivery: Sublingual ketamine tablets shipped to your home from a licensed pharmacy, with adult-signature verification and clear dosing instructions. No clinic visits required for treatment itself.
3. Preparation and integration: Licensed therapists help you set intentions before each session and process what comes up afterward. The focus is on practical strategies you can apply between sessions, not just talking about how treatment went.
4. Ongoing monitoring: Your clinical team tracks your mood, symptoms, and progress and adjusts your protocol as you go. If something needs to change, they're already watching for it.

Pricing: Treatment plans start at $54 per session with insurance (Foundation Plan: $599 for 8 sessions; Extended Plan: $1,299 for 24 sessions). Self-pay options are available for those without coverage ($83–125/session). Insurance coverage is currently available in California and New York, with over 22 million people eligible through existing partnerships.

Program outcomes: In Innerwell's outcome data, 87% of people see improvement within four weeks, with a 69% reduction in depression symptoms and 60% reduction in anxiety symptoms after 10 weeks. The program carries a 4.7 out of 5 average rating.

Take the free assessment to see if ketamine therapy might work for you.

Frequently Asked Questions

Can I take ketamine while still on my antidepressant?

In many cases, yes. Ketamine doesn't have the dangerous interactions with SSRIs or SNRIs that MAOIs do, and the FDA has approved esketamine for use both alongside and without oral antidepressants. Your clinical team will review your complete medication list before starting. Medications like benzodiazepines can increase sedation during treatment, so that's something they'd account for.

How long do ketamine's effects last, and can it replace my antidepressant?

A single dose often produces antidepressant effects lasting several days and up to about a week. With repeated treatments, many people sustain benefits over weeks, though optimal maintenance schedules are still being refined. Ketamine isn't a direct replacement for daily antidepressants. It works on a different model of treatment courses with maintenance sessions as needed. Some people taper their antidepressants after responding well to ketamine, but that's something you'd work through with your clinical team.

If I choose ketamine, do I need to go to a clinic?

Not necessarily. Spravato (esketamine nasal spray) requires visits to certified facilities with two-hour post-treatment observation. At-home sublingual ketamine programs offer more flexibility but remain off-label. Your insurance coverage, schedule, and clinical needs all factor into which format fits best.

Should I try another antidepressant or switch to ketamine?

This depends on how many medications you've tried and how you've responded. If you've only tried one or two SSRIs, switching to a different class (an SNRI, bupropion, or mirtazapine) is reasonable. The STAR*D trial showed about 30% of people remit with a second medication. But after two or more adequate trials across different classes, remission rates drop to roughly 14%, and the case for trying ketamine's glutamate-based approach becomes stronger.